Ron Wyden actually said...

As chairman of the Pricing, Reimbursement, and Access Steering Committee for Lilly USA and as the relevant profit and loss business unit leader for the biomedicines business unit for the United States, I approved pricing recommendations for this medicine.

Context

Wyden cites Azar's role in pricing strategies for a specific drug during his tenure at Lilly USA.

01/08/2018

https://www.congress.gov...

More Ron Wyden Quotes

View All Ron Wyden Quotes